about
Value of Antral Nodularity for the Diagnosis of Helicobacter pylori Infection in Children.Invasive Haemophilus influenzae Serotype f Case Reports in Mazovia Province, Poland.Induction Therapy With Biosimilar Infliximab in Children With Crohn Disease.Immunogenicity of Pertussis Booster Vaccination in Children and Adolescents with Inflammatory Bowel Disease: A Controlled Study.Gastroesophageal Reflux Disease in Children with Interstitial Lung Disease.Enterotoxigenic Clostridium perfringens infection and pediatric patients with inflammatory bowel disease.Overweight and obesity in children with newly diagnosed inflammatory bowel disease.Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial.A Two-Week Fecal Microbiota Transplantation Course in Pediatric Patients with Inflammatory Bowel Disease.Serotype-Specific Pneumococcal Status prior to PCV 13 Administration in Children and Adolescents with Inflammatory Bowel Disease.Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary ObservationsLack of effect of Lactobacillus GG in breast-fed infants with rectal bleeding: a pilot double-blind randomized controlled trial.A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in childrenImmunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel diseaseImmunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Pediatric Patients with Inflammatory Bowel DiseaseThe effectiveness of Lactobacillus reuteri DSM 17938 as an adjunct to macrogol in the treatment of functional constipation in children. A randomized, double-blind, placebo-controlled, multicentre trial
P50
Q35794333-BED32102-D3D1-4DAD-AD37-90EED93358B3Q36566959-B7D5686F-A023-4840-BE63-7382E98DD813Q38765158-CBBD9A6C-EDFD-430F-930B-6B7CF8585DA7Q38844359-140C6108-A8A9-4618-837E-9CDC678D25C5Q39858609-75C19011-F7B1-4201-8331-5E40D86AE8A9Q44606113-3A71BE5B-251F-46A8-A882-4A6D9671CF67Q45055913-0654DFB7-E252-4B86-8470-2BDCC4209BCDQ47691053-61258662-D8BD-4281-9B3E-95E919BA1E29Q49904375-6ACDAAD4-2601-4F76-B1BF-E08B91BCD5A7Q51711435-ACFFEE6C-64AD-43CC-8A6A-2FA4118B0C0EQ60609835-2CA772EE-0328-4689-942E-15A88228711AQ64988025-BF9A6F67-E44A-4721-81BD-5C4D8B492DC4Q79576838-426E5D0B-4DF0-4052-98B8-4F6EB3D6DFFEQ84984314-195DDD2E-35B8-4391-9BF7-256E0667DCA6Q87204179-9AC6138D-8D11-4409-A6CA-FEBA55EA3E3FQ88345036-482BBAAF-1CFF-4E46-A9D8-38A97259D3B2
P50
description
investigador
@es
researcher
@en
name
Agnieszka Gawrońska
@en
Agnieszka Gawrońska
@nl
type
label
Agnieszka Gawrońska
@en
Agnieszka Gawrońska
@nl
altLabel
Gawrońska A
@en
prefLabel
Agnieszka Gawrońska
@en
Agnieszka Gawrońska
@nl
P31
P496
0000-0001-6521-1050